Kestra Medical Technologies (NASDAQ:KMTS) Now Covered by Analysts at Oppenheimer

Oppenheimer began coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS) in a report released on Tuesday, Marketbeat Ratings reports. The firm set a “market perform” rating on the stock.

A number of other equities research analysts have also issued reports on KMTS. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research note on Wednesday, July 15th. The Goldman Sachs Group dropped their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. BTIG Research increased their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. Finally, Wall Street Zen cut Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $27.83.

Kestra Medical Technologies Price Performance

Shares of NASDAQ:KMTS opened at $23.24 on Tuesday. The company has a market capitalization of $1.36 billion, a P/E ratio of -9.60 and a beta of 0.47. Kestra Medical Technologies has a 1-year low of $14.10 and a 1-year high of $30.00. The firm’s 50 day simple moving average is $22.31 and its two-hundred day simple moving average is $22.66. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.41 and a quick ratio of 4.41.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The firm had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. Research analysts expect that Kestra Medical Technologies will post -2.3 EPS for the current fiscal year.

Insider Transactions at Kestra Medical Technologies

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock in a transaction on Monday, June 15th. The shares were sold at an average price of $20.81, for a total value of $312,150.00. Following the sale, the insider directly owned 395,467 shares in the company, valued at approximately $8,229,668.27. The trade was a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its stake in Kestra Medical Technologies by 137.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock worth $115,878,000 after acquiring an additional 2,529,851 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Kestra Medical Technologies by 180.8% during the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after acquiring an additional 612,343 shares during the last quarter. Millennium Management LLC bought a new position in shares of Kestra Medical Technologies during the 1st quarter valued at approximately $11,036,000. Brown Advisory Inc. grew its holdings in shares of Kestra Medical Technologies by 34.1% in the fourth quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after purchasing an additional 428,996 shares in the last quarter. Finally, Summit Partners Public Asset Management LLC bought a new stake in Kestra Medical Technologies in the fourth quarter worth $9,282,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.